Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk

Trial Profile

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MARINER
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 23 May 2017 This trial has been completed in Slovakia.
    • 08 May 2017 Planned End Date changed from 9 May 2018 to 25 May 2018.
    • 08 May 2017 Planned primary completion date changed from 22 Feb 2018 to 25 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top